Cargando…
Liposome encapsulation of doxorubicin and celecoxib in combination inhibits progression of human skin cancer cells
Therapeutic agents aimed at inhibiting a single molecular target have not been successful in cancer therapy, but rather they impart resistance. However, multi-target inhibitors have shown promising results in circumventing the development of resistance and inducing apoptosis in cancer cells/tissues....
Autor principal: | Singh, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5863640/ https://www.ncbi.nlm.nih.gov/pubmed/29593389 http://dx.doi.org/10.2147/IJN.S124701 |
Ejemplares similares
-
Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model
por: Islam, Md. Rakibul, et al.
Publicado: (2022) -
Doxorubicin combined with celecoxib inhibits tumor growth of medullary thyroid carcinoma in xenografted mice
por: MENG, XIANYING, et al.
Publicado: (2014) -
An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological and therapeutic evaluation.
por: Gokhale, P. C., et al.
Publicado: (1996) -
Evidence of more ion channels inhibited by celecoxib: K(V)1.3 and L-type Ca(2+) channels
por: Frolov, Roman V, et al.
Publicado: (2015) -
Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice
por: Murugesan, Kalaimathi, et al.
Publicado: (2020)